BIOAGE Labs EV/FCF

Que fait BIOAGE Labs ? BIOAGE Labs Inc, with ticker BIOA and ISIN US09077V1008, is a US-based pharmaceutical company headquartered in Richmond, California. The company operates within the Health Care sector and has approximately 60 employees. BIOAGE Labs Inc completed its initial public offering (IPO) on September 26, 2024. The company's website is https://bioagelabs.com. BIOAGE Labs Inc focuses on developing therapeutic product candidates for metabolic diseases, including obesity, through targeting the biology of human aging. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ). Azelaprag demonstrated potential to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. The company has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag is also being explored as an oral regimen to reduce weight loss and improve body composition in patients using obesity therapy with incretin drugs. Additionally, BIOAGE Labs Inc is developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. The company's preclinical programs leverage insights from its discovery platform, which is built on human longevity data, to address key pathways in metabolic aging. BIOAGE Labs est l'une des entreprises les plus populaires sur Eulerpool.